Hematological VitroScreen
- Services
- Hematological VitroScreen
![Patient primary never-passaged Hematological models for screening. Patient primary never-passaged Hematological models for screening.](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/43.jpg?width=1200&height=803&name=43.jpg)
Industry-leading Hematologic Model Screening
Champions' Hematological VitroScreens offer a quick, cost-effective solution to test your therapeutics in an ex vivo hematologic assay evaluating efficacy and mechanisms of action in primary patient samples.
-
Largest primary hematological repository of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM) models
-
Well-characterized models featuring patient responses, clinical annotation, NGS data (WES and RNASeq), deep phenotyping using flow cytometry, proteomics, and phospho-proteomics datasets available in Lumin
Data-Driven Insights to Accelerate Your Hematologic Program
![VitroScreen results in AML and B-ALL models in response to Standards of Care.](https://www.championsoncology.com/hs-fs/hubfs/VitroScreen%20SoC_2023.png?width=2000&name=VitroScreen%20SoC_2023.png)
Hematological VitroScreen Endpoints
![imaging](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/imaging.png?width=200&height=233&name=imaging.png)
![IHC](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/IHC.png?width=200&height=233&name=IHC.png)
![Flow](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/Flow.png?width=200&height=233&name=Flow.png)
![NGS](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/NGS.png?width=200&height=233&name=NGS.png)
![Western Blot](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/Western%20Blot.png?width=200&height=233&name=Western%20Blot.png)
![Luminex](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/Luminex.png?width=200&height=233&name=Luminex.png)
![Colony](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/Colony.png?width=200&height=233&name=Colony.png)
![DNA](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/DNA.png?width=200&height=233&name=DNA.png)
![Proteomics](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/Proteomics.png?width=200&height=233&name=Proteomics.png)
![Cell](https://www.championsoncology.com/hs-fs/hubfs/Website%202023/Cell.png?width=200&height=233&name=Cell.png)
The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology (IO) drugs in only 4 days using primary patient models.
In this study, we present an integrative analysis of multiple omic datasets coupled with phenotypic and therapeutic response profiles of Cytarabine from a cohort of primary Acute Myeloid Leukemia (AML) tumors, and Olaparib from a cohort of Patient-Derived Xenograft (PDX) models of ovarian cancer. These analyses, termed Pharmaco-Pheno- Multiomic (PPMO) Integration, established novel complex biomarker profiles that were used to accurately predict prospective therapeutic response profiles in cohorts of newly profiled AML and ovarian tumors.